? FLOW CYTOMETRY SHARED RESOURCE The Flow Cytometry Shared Resource?s (FCSR) primary goal is to provide support for the use of flow cytometric services by Cancer Center investigators and, regionally, to the greater basic research community.
The specific aims are to: (i) provide state-of-the-art technological capability for high-quality, multi-parameter analyses and/or sorting of different cell types from homogeneous or mixed cell populations via staff or user- friendly operation; (ii) provide training and ongoing support in basic and advanced user-friendly operations, as well as expertise to assist investigators in choosing reagents or instrument conditions that optimize the use of cytometry for their experimental needs; (iii) advise and provide technical support for analysis of flow cytometry data for publication, research presentations, and grant applications, along with management of cytometric data. The services provided by the facility include sample acquisition and analysis, cell sorting, on-site instrument maintenance, training, advice, and consultation. Currently, the FCSR houses a Becton-Dickinson (BD) FACSAria II high-speed cell sorter (installed 2009), a MoFlo Astrios EQ high-speed cell sorter (2014), and the following user-friendly analysis instruments: 2 BD LSRIIs (18-color and 14-color), a BD FACSCelesta with a High Throughput Sampler (HTS) (12-color, 2016), and a BD FACSCalibur with a HTS. In addition, the FCSR provides access to an Amnis ImageStreamx imaging cytometry system. The FCSR physical plant includes additional workstations, a library of flow cytometry journals, protocol guides, and other references. Twenty-four- hour access is available for all investigator-operated analysis instruments, reserved through an on-line calendar system. In the last Cancer Center Support Grant budget cycle period, there were substantial improvements to equipment and infrastructure: first, the FCSR was relocated to a single laboratory of 1,137 NSF located in the west wing of the Cancer Center with ease of access for all Cancer Center investigators; second, the FCSR acquired a new cell sorter, a 7-laser, 32-parameter MoFlo AstriosEQ (NIH shared instrumentation grant, 1S10 OD017998, PI, Dr. Montaner), and a 3-laser, 12-color FACSCelesta analysis instrument (Institute-funded). During the past project period, Cancer Center members from all Programs have extensively utilized the FCSR to accomplish pivotal research projects and increase the priority and impact of grant applications and peer-reviewed publications. Ongoing improvements in the FCSR enable Cancer Center members to accomplish rapid, highly automated analyses of diverse cell populations for better phenotypical characterization of cellular subsets and their functional characterization. This is especially valuable in analyzing populations of blood or immune-system cells, as well as expression of fluorescent protein-expressing vectors. Cell sorting permits the sterile purification of these cells for subsequent experimentation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-52
Application #
10145611
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
52
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400

Showing the most recent 10 out of 741 publications